首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   21983篇
  免费   1650篇
  国内免费   873篇
耳鼻咽喉   487篇
儿科学   215篇
妇产科学   523篇
基础医学   1460篇
口腔科学   224篇
临床医学   1756篇
内科学   2311篇
皮肤病学   239篇
神经病学   309篇
特种医学   1705篇
外国民族医学   24篇
外科学   3850篇
综合类   3793篇
预防医学   483篇
眼科学   97篇
药学   731篇
  5篇
中国医学   112篇
肿瘤学   6182篇
  2024年   4篇
  2023年   224篇
  2022年   346篇
  2021年   611篇
  2020年   680篇
  2019年   618篇
  2018年   558篇
  2017年   601篇
  2016年   666篇
  2015年   655篇
  2014年   1212篇
  2013年   956篇
  2012年   1078篇
  2011年   1295篇
  2010年   1166篇
  2009年   1285篇
  2008年   1360篇
  2007年   1552篇
  2006年   1462篇
  2005年   1209篇
  2004年   1075篇
  2003年   948篇
  2002年   861篇
  2001年   826篇
  2000年   646篇
  1999年   470篇
  1998年   389篇
  1997年   320篇
  1996年   233篇
  1995年   196篇
  1994年   194篇
  1993年   123篇
  1992年   105篇
  1991年   99篇
  1990年   72篇
  1989年   46篇
  1988年   53篇
  1987年   44篇
  1986年   46篇
  1985年   47篇
  1984年   29篇
  1983年   21篇
  1982年   32篇
  1981年   22篇
  1980年   18篇
  1979年   18篇
  1978年   13篇
  1977年   10篇
  1976年   4篇
  1975年   7篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
刘凌云  毛涵  朱袭嘉 《天津医药》2022,50(9):902-906
目的 通过实验探讨慢病毒转染调控FoxM1表达对人肝内胆管细胞癌(ICC)增殖、侵袭能力及基质金属蛋白酶(MMP)-9和MMP-2表达的影响。方法 Western blot检测ICC细胞株HCCC-9810、RBE及SSP-25的FoxM1蛋白表达水平,选取表达量较低者作为上调FoxM1细胞株,较高者作为下调细胞株;将分别携带FoxM1质粒和shRNA的慢病毒载体转染目标上调和下调ICC细胞株,建立稳定上下调FoxM1的细胞株(Western blot验证);MTT法检测转染后细胞增殖力,Transwell侵袭实验检测细胞侵袭能力;qPCR检测各组稳定转染细胞株MMP-9及MMP-2 mRNA表达水平。结果 SSP-25的FoxM1蛋白表达最高,HCCC-9810最低,由此选取SSP-25作为下调FoxM1表达目标细胞株,HCCC-9810作为上调FoxM1表达目标细胞株。慢病毒转染成功构建稳定上调(HCCC-9810-FoxM1组)及下调FoxM1细胞株(SSP-25-shFoxM1组);HCCC-9810-FoxM1组增殖及侵袭能力明显高于HCCC-9810-Control组(均P<0.05),而SSP-25-shFoxM1组增殖及侵袭能力较SSP-25-Control组明显下降(均P<0.05);HCCC-9810-FoxM1组中MMP-9及MMP-2 mRNA表达较HCCC-9810-Control组明显升高,而SSP-25-shFoxM1组中MMP-9及MMP-2 mRNA表达较SSP-25-Control组明显降低(均P<0.01)。结论 FoxM1促进ICC细胞增殖及侵袭,可能调控MMP-9及MMP-2表达,也有可能作为ICC潜在的生物标志物。  相似文献   
3.
4.
AimsThe Short Course Oncology Treatment (SCOT) trial indicated that 3 months of adjuvant doublet chemotherapy was non-inferior to 6 months of treatment for patients with colorectal cancer, with considerably less toxicity. The SCOT trial results were disseminated in June 2017. The aim of this study was to understand if SCOT trial findings were implemented in Scotland.Materials and methodsA retrospective analysis was carried out on a dataset derived from a source population of 5.4 million people. Eligible patients were those with stage II or III colorectal cancer who received adjuvant chemotherapy. Logistic regression was applied to understand the extent of practice change to a 3-month adjuvant chemotherapy duration after the SCOT trial results were disseminated. Interrupted time series analysis was used to visualise differences in prescribing trends before and after June 2017 for the overall cohort, and by SCOT trial eligibility.ResultsIn total, 2310 patients were included in the study; 1957 and 353 treated pre- and post-June 2017, respectively. The median treatment duration decreased from 21 weeks (interquartile range 14–24) prior to June 2017 to 12 weeks (interquartile range 12–21 weeks) after June 2017 (P < 0.001). The proportion of patients receiving over 3 months of adjuvant treatment decreased from 75% to 42% (P < 0.001). This change was most noticeable for patients who met the SCOT trial eligibility criteria, and specifically for those with low-risk stage III disease and those treated with capecitabine and oxaliplatin (CAPOX). Although practice change occurred in all locations, there were differences between regions that could be explained by pre-SCOT trial prescribing trends.DiscussionA significant change in chemotherapy prescribing occurred after dissemination of the SCOT trial results. National, real-world data can be used to capture the extent of implementation of clinical trial results. In this case, implementation was aligned with clinical trial subgroup findings. This type of analysis could be conducted to evaluate the impact of other clinical trials.  相似文献   
5.
针对可穿戴睡眠监测缺乏有效的自动睡眠分期和睡眠质量评价方法这一问题,提出一种适用于睡眠呼吸暂停综合征患者的自动睡眠分期方法。通过心电图R-R间期序列,分别得到心率变异性、呼吸幅度变异性和呼吸率变异性信号。以此为基础,提取时域、频域及非线性特征共55个。利用门控循环单元网络,分别构建清醒-睡眠二分类、清醒-快速眼动-非快速眼动睡眠三分类、清醒-快速眼动-浅睡-慢波睡眠四分类、清醒-快速眼动-非快速眼动Ⅰ-Ⅱ-Ⅲ期五分类等共4个不同分类粒度的睡眠分期模型;采用损失函数类别加权方法,有效降低数据非平衡对分期结果的影响。验证数据来自SHRS数据库的274例患者。借助准确率、Cohen's Kappa系数和睡眠结构指标对该睡眠分期方法进行性能评价。结果表明4个分类器的准确率分别为85.06%、75.44%、63.80%、62.13%,Cohen's Kappa系数达到了0.54、0.49、0.41、0.41,睡眠结构分析评估与临床结果之间的差异无统计学意义。所提出的方法基本满足睡眠质量评估的需求,适用于可穿戴睡眠监测应用。  相似文献   
6.
陈明武  王开宇  杨波  郑诗豪 《天津医药》2022,50(12):1246-1253
目的 探讨长链非编码RNA(lncRNA)OPA相互作用蛋白5反义转录本1(OIP5-AS1)对脑胶质瘤细胞增殖、凋亡、迁移和侵袭的影响机制。方法 收集33例胶质瘤患者(低级别胶质瘤14例、高级别胶质瘤19例)和33例颅脑损伤患者的组织标本。实时荧光定量PCR(qPCR)检测组织和细胞中OIP5-AS1、微小RNA-942-5p(miR-942-5p)和检查点激酶1(CHEK1)mRNA表达,分析胶质瘤组织中OIP5-AS1、miR-942-5p和CHEK1 mRNA表达水平的相关性。体外培养人脑胶质瘤细胞系U87、SHG-44、U251、H4和正常人星形胶质细胞NHA,Western blot检测细胞中CHEK1蛋白表达。将U87细胞分为对照(NC)组、siRNA阴性对照(si-NC)组、OIP5-AS1 siRNA(si-OIP5-AS1)组、si-OIP5-AS1+inhibitor阴性对照(si-OIP5-AS1+anti-NC)组、si-OIP5-AS1+miR-942-5p抑制剂(si-OIP5-AS1+anti-miR-942-5p)组,采用Lipofectamine 3000试剂进行转染。转染后,qPCR和Western blot检测细胞中OIP5-AS1、miR-942-5p和CHEK1 mRNA和蛋白表达水平;MTT法测定细胞增殖活性;流式细胞术检测细胞凋亡;Transwell实验检测细胞迁移和侵袭能力。最后通过双荧光素酶和RNA免疫沉淀(RIP)实验验证OIP5-AS1和miR-942-5p以及CHEK1和miR-942-5p的相互作用。结果 OIP5-AS1和CHEK1在脑胶质瘤组织和细胞中过表达,miR-942-5p呈低表达(均P<0.05);相关分析显示,脑胶质瘤组织中OIP5-AS1与miR-942-5p的表达水平呈负相关,miR-942-5p与CHEK1 mRNA的表达水平呈负相关,CHEK1与OIP5-AS1 mRNA的表达水平呈正相关;且OIP5-AS1、CHEK1 mRNA在高级别胶质瘤组织中的表达明显高于低级别组织,而高级别胶质瘤中的miR-942-5p水平明显低于低级别组织(P<0.01)。沉默OIP5-AS1可显著上调miR-942-5p,抑制CHEK1的mRNA和蛋白表达(均P<0.05);沉默OIP5-AS1可显著抑制U87细胞增殖、迁移和侵袭,促进U87细胞凋亡(均P<0.05);下调miR-942-5p可上调CHEK1表达,阻断OIP5-AS1沉默对脑胶质瘤细胞生物学行为的影响(均P<0.05)。双荧光素酶和RIP实验证实miR-942-5p是OIP5-AS1的靶基因,CHEK1是miR-942-5p的下游靶基因。结论 沉默OIP5-AS1可能通过上调miR-942-5p抑制CHEK1表达,抑制脑胶质瘤细胞的侵袭和迁移,并促进细胞凋亡。  相似文献   
7.
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一类起源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物的少见肿瘤,可发生于全身各处,以肺及胃肠胰NEN(gastroenteropancreatic neuroendocrine neoplasm, GEP-NEN)最常见。国内外研究数据均提示,NEN的发病率在不断上升。美国流行病学调查结果显示,与其他类型肿瘤相比,NEN的发病率上升趋势更为显著。中国抗癌协会神经内分泌肿瘤专委会在现有循证医学证据基础上,结合已有国内外指南和共识,制订了首版中国抗癌协会神经内分泌肿瘤诊治指南,为临床工作者提供参考。  相似文献   
8.
《Cancer radiothérapie》2022,26(8):1034-1044
PurposeAssess the feasibility of a randomized controlled trial (RCT) exploring the use of medical imaging as a therapeutic education (TPE) intervention in external radiation therapy.Materials and methodsExperimental feasibility trial of “RCT” type carried out in a single-center, between November 2019 and March 2020, following adult patients treated by thoracic radiotherapy. In addition to the information usually given, the experimental group benefited from an intervention consisting in the visualization of their own medical images using the open-source software “Stone of Orthanc”.ResultsForty-nine patients were recruited with a refusal rate of 8.16% (4/49). 20 patients were withdrawn from the study for health reasons (COVID), 10 for medical reasons. All the remaining 15 participants completed the process. Although not significant, the experimental group showed a median gain in the perception of knowledge compared to the control group (+ 1.9 (1.6 – 2.2)) vs (+ 1.4 (1.4 – 1.8)), as well as a decrease in scores related to anxiety (? 3.0 (?4.5 - (?2.0)) vs ? 1.0 (?5.0 - 0.0)) and emotional distress ((? 5.0 (? 7.5 - (? 3.5)) vs (? 2.0 (? 5.0 - (? 1.0)) A significant reduction (p = 0.043) is observed for the depression score ((? 2.0 (?3.0 - (?1.5)) vs (0.0 (0.0 – 0.0)).ConclusionThis study demonstrates the feasibility of the project, with promising preliminary results. Some adaptations in order to conduct a larger-scale RCT are highlighted.  相似文献   
9.
目的: 探讨磁共振成像(magnetic resonance imaging,MRI)对肛周化脓性汗腺炎( hidradenitis suppurativa,HS)诊断分期及治疗的临床应用价值。方法: 回顾性分析2018年1月至2020年12月就诊于包头医学院第二附属医院皮肤科及肛肠科的肛周HS患者的临床及MRI资料,结合临床Herley 分期,观察MRI显示的HS病灶分布与严重程度。结果: 10例患者中Herley Ⅰ期6例,Ⅱ期 4例,Ⅰ期患者MRI表现为局灶性炎症及脓肿,未见窦道。脓肿见于肛周(83 %),之后依次为臀区(50 %)、前会阴区(33 %)。Ⅱ期患者MRI表现为皮下组织炎症、脓肿及窦道,窦道未侵犯肌肉、肛管,未见窦道相互连接。4例患者中窦道见于肛周(100 %),前会阴区(25 %),臀区(25 %),坐骨直肠窝(25 %),臀沟(25 %)。脓肿见于肛周(100 %),前会阴区(50 %),臀区(50 %),坐骨直肠窝(25 %),臀沟(25 %)。本组患者MRI表现与临床分期一致。结论: MRI检查可明确肛周HS病变范围及深度,确定Herley 分期,为肛周HS的诊断、治疗及疗效判定提供客观的影像学依据。  相似文献   
10.
BackgroundIn order to avoid excessive treatment of thyroid nodules in the clinic, it is necessary to find a simple and practical analysis method to comprehensively and accurately reflect benign or malignant thyroid nodules. This study aimed to construct and validate a comprehensive and reliable network-based predictive model using a variety of imaging and laboratory criteria for thyroid nodules to stratify the risk of malignancy prior to surgery.MethodsWe retrospectively analyzed data from patients who underwent surgical treatment for thyroid nodules at the Thyroid and Breast Diagnosis and Treatment Center of Weifang Hospital of Traditional Chinese Medicine between January 2018 and December 2020. Binary logical regression analysis was performed to predict whether nodules were malignant or benign. The developmental dataset included 457 patients (January 2018–December 2020). The validation set included separate data points (n = 225, January 2018–December 2020).ResultsIn this study, criteria that showed significant predictive value for malignant nodules included TI-RADS: 4b (p = 0.065); Bethesda IV, Bethesda V, Bethesda VI (P < 0.0001); BRAFV600E mutation (P < 0.0001); Calcitonin>5 pg/ml (p = 0.0037); and FNA-Tg>30 ng/ml (p = 0.0003). A 10-grade risk scoring system was developed. The risk of malignancy risk ranged from 2.06% to 100% and was positively associated with increasing risk grade. The areas under the receiver-operating characteristic curve of the development and validation sets were 0.972 and 0.946, respectively.ConclusionA simple, comprehensive and reliable web-based predictive model was designed using a variety of imaging and laboratory criteria to stratify thyroid nodules by probability of malignancy.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号